[Treatment of impotence with intracavernous auto-injections: moxisylyte diminishes the risks compared to papaverine].
The alpha-blocking agent Moxisylyte was tested in auto-intracavernous injections (auto-ICI) in 72 impotent patients. The side-effects were compared to those observed in a group of 34 impotent patients treated with auto-ICI of Papaverine during the same period of time. The Moxisylyte auto-ICI improved 83% of the patients including 68% reporting a complete and durable success. Moxisylyte proved to be safer due to a reduced rate of prolonged erections (1.3% of the patients versus 8.8% with Papaverine) and corporeal fibrosis (1.3% versus 32% with Papaverine). Though less potent than Papaverine, and often seeming insufficient when tested in the office, this type of alpha-blocking agent could be tried in a first time in most candidates to auto-ICI before resorting to Papaverine or Prostaglandin E1 if it fails.
Association pour l'Etude de la Pathologie de l'Appareil Reproducteur et de la Psychosomatique (EPARP), Lille.
J
J
Buvat
M
M
Buvat-Herbaut
A
A
Lemaire
G
G
Marcolin
D000328:Adult; D000368:Aged; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D013948:Moxisylyte / Q000627:therapeutic use*; D010208:Papaverine / Q000627:therapeutic use*; D010411:Penile Induration / Q000139:chemically induced / Q000453:epidemiology; D010413:Penis; D011317:Priapism / Q000139:chemically induced / Q000453:epidemiology; D012646:Self Administration; D013997:Time Factors; D016896:Treatment Outcome
D010208:Papaverine; D013948:Moxisylyte
Traitement de l'impuissance par auto-injections intracaverneuses: le moxisylyte diminue les risques par comparaison avec la papavérine.